ABBOTT LABORATORIES Treasury Stock, Common, Value
ABBOTT LABORATORIES (ABT) had Treasury Stock, Common, Value of $16.93 billion as of 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:TreasuryStockCommonValue · last filed 2026-04-29
- 2026-03-31: Treasury Stock, Common, Value $16.93B.
- 2025-12-31: Treasury Stock, Common, Value $17.18B.
- 2025-09-30: Treasury Stock, Common, Value $16.88B.
- 2025-06-30: Treasury Stock, Common, Value $16.61B.
| Period end | Treasury Stock, Common, Value |
|---|---|
| 2026-03-31 | $16.93B 10-Q · filed 2026-04-29 |
| 2025-12-31 | $17.18B 10-Q · filed 2026-04-29 |
| 2025-09-30 | $16.88B 10-Q · filed 2025-10-29 |
| 2025-06-30 | $16.61B 10-Q · filed 2025-07-30 |
| 2025-03-31 | $16.61B 10-Q · filed 2025-04-30 |
| 2024-12-31 | $16.84B 10-K · filed 2026-02-20 |
| 2024-09-30 | $16.48B 10-Q · filed 2024-10-31 |
| 2024-06-30 | $15.76B 10-Q · filed 2024-07-31 |
| 2024-03-31 | $15.76B 10-Q · filed 2024-05-02 |
| 2023-12-31 | $15.98B 10-K · filed 2025-02-21 |
| 2023-09-30 | $15.69B 10-Q · filed 2023-11-01 |
| 2023-06-30 | $15.72B 10-Q · filed 2023-08-03 |
| 2023-03-31 | $15.31B 10-Q · filed 2023-05-04 |
| 2022-12-31 | $15.23B 10-K · filed 2024-02-16 |
| 2022-09-30 | $14.55B 10-Q · filed 2022-11-01 |
| 2022-06-30 | $13.72B 10-Q · filed 2022-08-02 |
| 2022-03-31 | $13.73B 10-Q · filed 2022-05-03 |
| 2021-12-31 | $11.82B 10-K · filed 2023-02-17 |
| 2021-09-30 | $11.00B 10-Q · filed 2021-11-03 |
| 2021-06-30 | $10.34B 10-Q · filed 2021-08-04 |
| 2021-03-31 | $9.85B 10-Q · filed 2021-05-05 |
| 2020-12-31 | $10.04B 10-K · filed 2022-02-18 |
| 2020-09-30 | $9.87B 10-Q · filed 2020-11-04 |
| 2020-06-30 | $9.90B 10-Q · filed 2020-07-29 |
| 2020-03-31 | $9.91B 10-Q · filed 2020-04-29 |
| 2019-12-31 | $10.15B 10-K · filed 2021-02-19 |
| 2019-09-30 | $9.63B 10-Q · filed 2019-10-31 |
| 2019-06-30 | $9.66B 10-Q · filed 2019-07-31 |
| 2019-03-31 | $9.68B 10-Q · filed 2019-05-01 |
| 2018-12-31 | $9.96B 10-K · filed 2020-02-21 |
| 2018-09-30 | $9.86B 10-Q · filed 2018-10-31 |
| 2018-06-30 | $9.91B 10-Q · filed 2018-08-01 |
| 2018-03-31 | $9.95B 10-Q · filed 2018-05-02 |
| 2017-12-31 | $10.22B 10-K · filed 2019-02-22 |
| 2017-09-30 | $10.29B 10-Q · filed 2017-11-02 |
| 2017-06-30 | $10.36B 10-Q · filed 2017-08-02 |
| 2017-03-31 | $10.38B 10-Q · filed 2017-05-03 |
| 2016-12-31 | $10.79B 10-K · filed 2018-02-16 |
| 2015-12-31 | $10.62B 10-K · filed 2017-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |